BioMed Research International
Volume 2019 (2019), Article ID 3202838, 8 pages
https://doi.org/10.1155/2019/3202838

Research Article

Meta-Analysis of the Effects of Cardiac Rehabilitation on Exercise Tolerance and Cardiac Function in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy

Zhang-bing Chen,¹ Liu-bo Fan,¹ Ya-jing Liu,¹ and Ya-ru Zheng²

¹Department of Rehabilitation, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
²Department of Cardiovascular Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China

Correspondence should be addressed to Ya-ru Zheng; yaruswing@126.com

Received 30 July 2019; Revised 15 October 2019; Accepted 25 October 2019; Published 28 November 2019

Academic Editor: José L. Campos

Copyright © 2019 Zhang-bing Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Objective. To evaluate the effects of cardiac rehabilitation on exercise tolerance and cardiac function in heart failure patients undergoing cardiac resynchronization therapy (CRT). Methods. Randomized controlled trials were initially identified from systematic reviews of the literature about cardiac rehabilitation and heart failure patients with CRT. We undertook updated literature searches of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, CBM, CNKI, and Wanfang databases until July 1, 2017. STATA12.0 software was used. Results. Four randomized controlled studies were included. The total sample size was 157 patients, including 77 in the control group. Cardiac rehabilitation treatment affected the peak VO₂ in heart failure patients with CRT (, I² = 0%). The results lacked heterogeneity, and the data were merged in a fixed-effects model (WMD = 2.17 ml/kg/min, 95% CI (1.42, 2.92), ). The peak VO₂ was significantly higher in the cardiac rehabilitation group than in the control group. The sensitivity analysis showed that the results of the meta-analysis were robust. Cardiac rehabilitation treatment affected LVEF in heart failure patients with CRT (, I² = 63.6%); the heterogeneity among the various research results meant that the data were merged in a random-effects model (WMD = 4.75%, 95% CI (1.53, 7.97), ). The LVEF was significantly higher in the cardiac rehabilitation group than in the control group. The sources of heterogeneity were analyzed, and it was found that one of the studies was the source of significant heterogeneity. After the elimination of that study, the data were reanalyzed, and the heterogeneity was significantly reduced. There were still significant differences in the WMD and 95% CI. Conclusion. Cardiac rehabilitation can improve exercise tolerance and cardiac function in heart failure patients with CRT. Future studies are needed to evaluate whether these beneficial effects of cardiac rehabilitation may translate into an improvement in long-term clinical outcomes among these patients.

1. Introduction

The incidence of chronic heart failure is increasing annually [1, 2]. In developed countries, the prevalence rate in people over 70 years old is more than 10% [3]. In patients with severe left ventricular systolic heart failure, approximately one-third have ventricular systolic dyssynchrony [4]. In this group of patients, cardiac resynchronization therapy (CRT) can effectively improve exercise tolerance, heart function, quality of life, prognosis, and mortality [5–8]. A large number of clinical studies have shown that cardiac rehabilitation exercise can significantly improve exercise tolerance, cardiac function, quality of life, mortality, and prognosis in patients with heart failure [9, 10]. However, most cardiac rehabilitation studies included only patients with cardiac function classified as NYHA I-II, and few studies were performed on those with cardiac function classified as NYHA II-IV, especially NYHA III-IV. The HF-ACTION study showed that cardiac rehabilitation is safe and effective in NYHA II-IV heart failure patients [11]. Both cardiac rehabilitation exercise and CRT can improve the prognosis of patients with heart failure, but the effect of the combined intervention is still unclear. Due to the small sample size, the inconsistent results, and the lack of systematic evaluation of the quality of the clinical studies, the role of cardiac rehabilitation in patients with heart failure after CRT is still controversial. Therefore, this study aimed at exploring the impact of cardiac rehabilitation therapy on patients with heart failure after CRT and at conducting a systematic, objective, quantitative comprehensive analysis of the existing research results to provide more evidence-based guidance for the treatment of heart failure.

2. Materials and Methods

2.1. Literature Search Strategy

We searched for randomized controlled trials from January 1, 1990, to July 1, 2017, in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Data, and China Biology Medicine databases. The keywords used for this search were as follows: (rehabilitation or exercise), cardiac resynchronization therapy, and heart failure. The reference lists of the included studies were also searched for relevant results.

2.2. Literature Selection Criteria

Two investigators (Zhang-bing Chen and Ya-jing Liu) independently reviewed all the studies retrieved from the database searches. We followed the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Figure 1). The selection criteria for this meta-analysis were as follows: (1) studied the effect of cardiac rehabilitation therapy on patients with heart failure after CRT; (2) measured at least peak oxygen uptake (peak VO₂) or left ventricular ejection fraction (LVEF); and (3) follow-up time less than 6 months. The exclusion criteria were as follows: (1) nonrandomized controlled trial; (2) non-CRT patients with heart failure; (3) interventions that did not include or directly study cardiac rehabilitation and CRT; (4) missing or insufficient original data; (5) repeated reports from the same study; (6) lacking the full text; and (7) follow-up time unclear.

Figure 1: Flow diagram of the study selection procedure used for this meta-analysis of the effects of cardiac rehabilitation on exercise tolerance and cardiac function in heart failure patients with CRT.

2.3. Data Extraction

Two reviewers (Zhang-bing Chen and Ya-jing Liu) extracted the papers independently. We initially reviewed the article titles and abstracts and then excluded those that did not fit the inclusion criteria. All the included studies were extensively reviewed. Any disagreements were resolved by discussion. For each included study, we assessed the methodological rigor and quality using the Cochrane Collaboration’s tool for assessing the risk of bias. The information that was extracted included the first author name, year of publication, sample size, follow-up time, LVEF, peak VO₂, cardiac rehabilitation protocol, and outcome.

2.4. Statistical Analysis

All analyses were performed using the STATA software package v12.0 (Stata Corporation, College Station, TX). Pooled effects were estimated by the weighted mean difference (WMD) and a 95% confidence interval (CI) to compare the cardiac rehabilitation group with the control group. We assessed heterogeneity using χ²-based Q-tests. I² values of 25%, 50%, and 75% represented low, medium, and high levels of heterogeneity, respectively. If or I² <50%, it was considered that all studies were homogeneous, and a fixed-effects model was selected for the meta-analysis. Otherwise, there was heterogeneity among the studies, and the random-effects model was used in the meta-analysis. Publication bias was assessed using Begg’s funnel plot and Egger’s linear regression test. values less than 0.05 were considered statistically significant.

3. Results

3.1. Study Selection

An initial search of the literature yielded 1436 publications. A total of 79 papers had subjects overlapping with other publications. A total of 364 studies were reviews; 937 studies were excluded according to the title and abstract. Then, full-text articles were retrieved and assessed on the basis of the inclusion criteria. Sixty papers were ineligible for the following reasons: 42 papers did not provide complete data for this meta-analysis, and 10 papers were not randomized controlled trials. In the end, 4 studies [12–15] were selected for CR on peak VO₂ in HF patients with CRT, and 3 studies [12–14] were selected for CR on LVEF in HF patients with CRT. A summary of the study selection process is shown in Figure 1. The characteristics of the included studies are summarized in Table 1.

Table 1: The characteristics of the included studies.

Author
Year
Sample size
Follow-up time (months)
Peak VO₂ (ml/kg/min, mean ± SD)
LVEF (%)
CR protocol (a: duration, b: frequency, c: exercise mode, d: intensity)
Outcome
Adverse events

Control
CR
Control
CR
Control
CR

Patwala et al. [12]
2009
25
25
3
18.07 ± 3.89
20.1 ± 3.84
35.0 ± 7.2
37.3 ± 5.4
(a) 12 weeks
(b) 3 sessions/week
(c) aerobic exercise, each session consisted of 10 min of treadmill walking, 10 min of cycling, and 10 min of treadmill walking
(d) moderate to high intensity, 80% of the peak heart rate achieved in the first 4 weeks, 85% in the next 4 weeks, and 90% in the final 4 weeks
Peak VO₂, NYHA class, exercise duration, QOL, several other measures of cardiopulmonary fitness, echocardiographic measures
No patients had any adverse events from the exercise training

Belardinelli et al. [13]
2006
10
15
2
15.8 ± 2.1
17.9 ± 2.3
33 ± 6
42 ± 5
(a) 8 weeks
(b) 3 sessions/week
(c) aerobic exercise, each session consisted of 15 min of stretching exercises, 40 min of cycling, and 5 min of loadless recovery
(d) moderate intensity, 60% of the peak VO₂
Peak VO₂, functional capacity, QOL, hospital readmission, echocardiographic measures
No patients had any adverse events from the exercise training

Nobre et al. [14]
2016
16
14
4
19.7 ± 1.2
21.6 ± 1.5
29 ± 2
33 ± 4
(a) 4 months
(b) 3 sessions/week
(c) aerobic exercise, each session consisted of 5 min of stretching exercises, 40 min of treadmill walking, 10 min of local strengthening exercises, and 5 min of cool down with stretching exercises
(d) moderate intensity, established by heart rate levels that corresponded to the anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test
Peak VO₂, muscle sympathetic nerve activity, exercise duration, echocardiographic measures, forearm blood flow, Ca²⁺ handling gene expression in vastus lateralis muscle
N/A

Smolis-Bak et al. [15]
2015
26
26
3-4/12
13.4 ± 4.2
17.2 ± 3.9

(a) 11 months
(b) initial exercise training in the hospital setting for 3 weeks on average, then at home with telemonitoring for 5 sessions/week
(c) aerobic exercise, active exercises of small and subsequently larger muscle groups of the lower and upper limbs, respiratory exercises, range-of-motion exercises of the shoulder joint on the implantation side
(d) low intensity
Peak VO₂, peak VCO₂, treadmill test duration, echocardiographic measures, QOL
No significant differences in ICD interventions, mortality, or hospitalization rates between the groups

CR: cardiac rehabilitation; peak VO₂: peak oxygen uptake; peak VCO₂: peak carbon dioxide elimination; LVEF: left ventricular ejection fraction; QOL: quality of life; N/A: not available; ICD: implantable cardioverter-defibrillator.

3.2. Effects of Cardiac Rehabilitation on Peak VO₂ in Heart Failure Patients with CRT

A total of 4 studies were included, and the heterogeneity test showed that and I² = 0%, suggesting homogeneity of all studies. The fixed-effects model was used to merge all data, and the results showed that the peak oxygen uptake of patients in the cardiac rehabilitation group was significantly higher than that in the control group, and the difference was statistically significant (WMD = 2.17 ml/kg/min, 95% CI (1.42, 2.92), ) (Figure 2).

Figure 2: Meta-analysis of the effects of cardiac rehabilitation on peak VO₂ in heart failure patients with CRT.

3.3. Effects of Cardiac Rehabilitation on LVEF in Heart Failure Patients with CRT

A total of 3 studies were included. The heterogeneity test (, I² = 63.6%) suggested that heterogeneity existed in the studies. Data were combined using the random-effects model, and the results were as follows: WMD = 4.75%, 95% CI (1.53, 7.97), , indicating that patients in the cardiac rehabilitation group had a significantly higher LVEF than those in the control group, and the difference was statistically significant (Figure 3). The Galbraith plot showed the sources of heterogeneity, and there was obvious heterogeneity in one of the studies (Figure 4). After the data from that study were removed, the heterogeneity was significantly reduced, and there were still significant differences in WMD and 95% CI: heterogeneity test, , I² = 0%; WMD = 3.49, 95% CI (1.55, 5.42), .

Figure 3: Meta-analysis of the effects of cardiac rehabilitation on LVEF in heart failure patients with CRT.

Figure 4: Galbraith plot of the heterogeneity of cardiac rehabilitation on LVEF in heart failure patients with CRT.

3.4. Publication Bias

Egger’s test revealed that there was no publication bias in the analyses for peak VO₂ (t = 1.32, ) (Figure 5(a)) and LVEF (t = 11.56, ) (Figure 5(b)). The shapes of the funnel plots do not show evidence of asymmetry.

(a)

(b)

Figure 5: Begg’s funnel plot of publication bias in the meta-analysis of the effects of cardiac rehabilitation on peak VO₂ (a) and LVEF (b) in heart failure patients with CRT.

4. Discussion

This meta-analysis found that cardiac rehabilitation appears to be safe and effective for high-risk heart failure patients with CRT. The included studies had varying exercise intensity, frequency, and duration. Most studies used moderate-intensity exercise, and the highest intensity was 90% of the peak heart rate. All cardiac rehabilitation programs lasted 2 to 4 months with the frequency of 3–5 sessions/week. Despite the varying exercise intensity, frequency, and duration, the programs were all well tolerated, and the patients did not have any complications from the exercise training. Nevertheless, in cardiac rehabilitation programs, all exercise training programs for heart failure patients should include at least a preliminary assessment with a cardiopulmonary exercise test and cardiac function evaluation [16]. The exercise training may be completely effective only when directly supervised by a physiotherapist or guided by telemonitoring. Appropriate education to promote a healthy and active lifestyle, controlled regular exercise, and motivation to safely increase the exercise load and intensity also play vital roles in the outcomes of heart failure patients [15].

Cardiac rehabilitation is a widely accepted treatment for patients with chronic heart failure [17]. However, cardiac rehabilitation should be considered a comprehensive management strategy. A variety of factors affect the outcome of cardiac rehabilitation, such as patient education, the type of exercise training, the medications prescribed, and psychosocial support [18]. CRT can significantly improve cardiac function in patients with heart failure but has little effect on the peripheral skeletal muscle [19]. However, appropriate and personalized cardiac rehabilitation significantly improves exercise duration, peak oxygen uptake, cardiac function, and peripheral skeletal muscle function [12, 20]. Therefore, in patients with heart failure undergoing cardiac rehabilitation after CRT, the clinical improvement of cardiac function level on the NHYA and quality of life is likely to be explained by the peripheral (muscular and vascular) and cardiac effects of CRT-induced cardiac function enhancement and cardiac rehabilitation exercise [16, 20, 21].

However, other research studies have shown that cardiac rehabilitation (3-4 months) significantly improves the effects of CRT on peak oxygen uptake and cardiac function in patients with heart failure, but prolonging the follow-up time to 12 months does not sustain this effect. Compared with the control group, cardiac rehabilitation failed to result in obviously improved activity tolerance and heart function at 12 months [15]. This result may be affected by the low intensity of home-based exercise training. A higher intensity of training may be required.

This study included a meta-analysis of peak oxygen uptake and LVEF, and the results showed that cardiac rehabilitation can significantly improve peak VO₂ (WMD 2.17 ml/kg/min, 95% CI 1.42, 2.92) and LVEF (WMD 4.75%, 95% CI 1.53, 7.97) in patients with heart failure undergoing cardiac rehabilitation after CRT and thus may further improve prognosis. The results of this study are consistent with those of most studies on cardiac rehabilitation after CRT, further demonstrating the role of cardiac rehabilitation in patients with heart failure after CRT.

Finally, as CRT is now increasingly used in heart failure patients, the telemonitoring of devices coupled with guided home-based training may be proposed to these patients, either alone or after an initial center-based cardiac rehabilitation program, in order to improve the long-term adherence [16, 22]. So far, there data pertaining to such programs are scarce [15]. Further studies are needed.

There are still some limitations in this study: (1) the number of included studies is not large, and the sample sizes of the included studies are relatively small, meaning that the findings need to be confirmed in large-sample, randomized, double-blind controlled trials; (2) cardiac rehabilitation in China is still in its initial stage, and the standards of cardiac rehabilitation in various research centers are not completely consistent. There are differences in intervention measures, leading to different subsequent influences.

5. Conclusions

In conclusion, cardiac rehabilitation can improve exercise capacity and cardiac function in heart failure patients with CRT. Future studies are needed to evaluate whether these beneficial effects of cardiac rehabilitation may translate into an improvement in long-term clinical outcomes among these patients.

Data Availability

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available in the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

P. Ponikowski, A. A. Voors, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC,” European Heart Journal, vol. 37, no. 27, pp. 2129–2220, 2016.

S. M. Hollenberg, L. Warner Stevenson, T. Ahmad et al., “ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of cardiology solution set oversight committee,” Journal of the American College of Cardiology, vol. 74, no. 15, pp. 1966–2011, 2019.

A. Mosterd and A. W. Hoes, “Clinical epidemiology of heart failure,” Heart, vol. 93, no. 9, pp. 1137–1146, 2007.

J. Cleland, K. Swedberg, F. Follath et al., “The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis,” European Heart Journal, vol. 24, no. 5, pp. 442–463, 2003.

J. G. F. Cleland, J.-C. Daubert, E. Erdmann et al., “The effect of cardiac resynchronization on morbidity and mortality in heart failure,” New England Journal of Medicine, vol. 352, no. 15, pp. 1539–1549, 2005.

C. Linde, W. T. Abraham, M. R. Gold, M. St. John Sutton, S. Ghio, and C. Daubert, “Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms,” Journal of the American College of Cardiology, vol. 52, no. 23, pp. 1834–1843, 2008.

A. J. Moss, W. J. Hall, D. S. Cannom et al., “Cardiac-resynchronization therapy for the prevention of heart-failure events,” New England Journal of Medicine, vol. 361, no. 14, pp. 1329–1338, 2009.

A. S. L. Tang, G. A. Wells, M. Talajic et al., “Cardiac-resynchronization therapy for mild-to-moderate heart failure,” New England Journal of Medicine, vol. 363, no. 25, pp. 2385–2395, 2010.

B. A. F. van Tol, R. J. Huijsmans, D. W. Kroon, M. Schothorst, and G. Kwakkel, “Effects of exercise training on cardiac performance, exercise capacity and quality of life in patients with heart failure: a meta-analysis,” European Journal of Heart Failure, vol. 8, no. 8, pp. 841–850, 2006.

M. F. Piepoli, C. Davos, D. P. Francis, and A. J. Coats, “Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH),” BMJ, vol. 328, no. 7433, p. 189, 2004.

N. Luo, P. Merrill, K. S. Parikh et al., “Exercise training in patients with chronic heart failure and atrial fibrillation,” Journal of the American College of Cardiology, vol. 69, pp. 1683–1691, 2017.

A. Y. Patwala, P. R. Woods, L. Sharp, D. F. Goldspink, L. B. Tan, and D. J. Wright, “Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured exercise training: a randomized controlled study,” Journal of the American College of Cardiology, vol. 53, no. 25, pp. 2332–2339, 2009.

R. Belardinelli, F. Capestro, A. Misiani, P. Scipione, and D. Georgiou, “Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy,” European Journal of Cardiovascular Prevention & Rehabilitation, vol. 13, no. 5, pp. 818–825, 2006.

T. S. Nobre, L. M. Antunes-Correa, R. V. Groehs et al., “Exercise training improves neurovascular control and calcium cycling gene expression in patients with heart failure with cardiac resynchronization therapy,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 311, no. 5, pp. H1180–H1188, 2016.

E. Smolis-Bak, R. Dabrowski, E. Piotrowicz et al., “Hospital-based and telemonitoring guided home-based training programs: effects on exercise tolerance and quality of life in patients with heart failure (NYHA class III) and cardiac resynchronization therapy. A randomized, prospective observation,” International Journal of Cardiology, vol. 199, pp. 42–47, 2015.

M. C. Iliou, J. C. Blanchard, A. Lamar-Tanguy, P. Cristofini, and F. Ledru, “Cardiac rehabilitation in patients with pacemakers and implantable cardioverter defibrillators,” Monaldi Archives for Chest Disease, vol. 86, no. 1-2, p. 756, 2016.

R. S. Taylor, S. Walker, N. A. Smart et al., “Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis,” Journal of the American College of Cardiology, vol. 73, no. 12, pp. 1430–1443, 2019.

K. J. Price, B. A. Gordon, S. R. Bird, and A. C. Benson, “A review of guidelines for cardiac rehabilitation exercise programmes: is there an international consensus?” European Journal of Preventive Cardiology, vol. 23, no. 16, pp. 1715–1733, 2016.

R. R. Kuniyoshi, M. Martinelli, C. E. Negrão et al., “Effects of cardiac resynchronization therapy on muscle sympathetic nerve activity,” Pacing and Clinical Electrophysiology, vol. 37, no. 1, pp. 11–18, 2014.

R. B. Thompson, C. R. Tomczak, and M. J. Haykowsky, “Evaluation of cardiac, vascular, and skeletal muscle function with MRI: novel physiological end points in cardiac rehabilitation research,” Canadian Journal of Cardiology, vol. 32, no. 10, pp. S388–S396, 2016.

A. Abreu and H. Santa Clara, “Imaging predictive factors and exercise training in CRT patients,” Monaldi Archives for Chest Disease, vol. 86, no. 1-2, p. 760, 2016.

E. Piotrowicz, T. Zieliński, R. Bodalski et al., “Home-based telemonitored Nordic walking training is well accepted, safe, effective and has high adherence among heart failure patients, including those with cardiovascular implantable electronic devices: a randomised controlled study,” European Journal of Preventive Cardiology, vol. 22, no. 11, pp. 1368–1377, 2015.